No Data
No Data
No Data
No Data
No Data
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients With Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
PR NewswireApr 24 22:20
AnaptysBio Names Thomas Smart as CEO >ANAB
AnaptysBio Names Thomas Smart as CEO >ANAB
Dow JonesApr 24 21:01
Press Release: Actym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to t
Dow JonesApr 24 21:00
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a rare, HP
PR NewswireMar 29 04:05
Precigen Shares Fall After Downgrade From JPMorgan
Precigen (PGEN) shares were down 9% in regular Friday trading after JPMorgan downgraded the company to underweight from neutral. Trading volume was nearly 1.5 million shares against a daily average of
MT NewswiresMar 23 04:14
Precigen Cut to Underweight From Neutral by JP Morgan
Precigen Cut to Underweight From Neutral by JP Morgan
Dow JonesMar 23 00:22
No Data
No Data